转自：安必平
向上滑动阅览
参考文献
[1] Carmona O, Kleinmann N, Zilberman DE, Dotan ZA, Shvero A. Do Urine Cytology and FISH Analysis Have a Role in the Follow-Up Protocol of Upper Tract Urothelial Carcinoma? Clin Genitourin Cancer. 2024 Feb;22(1):98-105. doi: 10.1016/j.clgc.2023.10.010. Epub 2023 Nov 2. PMID: 37996271.
[2] Kumar M, Kumar K, Singh HP, Nair S, Patel A, Kumar A, Soni S. Discordance between Fluorescence In Situ Hybridization and Immunohistochemistry Analysis of Anaplastic Lymphoma Kinase Rearrangement in Indian Patients with Non-Small Cell Lung Cancer. South Asian J Cancer. 2020 Jun;9(2):109-114. doi: 10.1055/s-0040-1721191. Epub 2020 Dec 14. PMID: 33354554; PMCID: PMC7745737.
[3] Lavery HJ, Zaharieva B, McFaddin A, Heerema N, Pohar KS. A prospective comparison of UroVysion FISH and urine cytology in bladder cancer detection. BMC Cancer. 2017 Apr 7;17(1):247. doi: 10.1186/s12885-017-3227-3. PMID: 28388880; PMCID: PMC5383950.
[4] Shang D, Liu Y, Xu X, Chen Z, Wang D. Diagnostic value comparison of CellDetect, fluorescent in situ hybridization (FISH), and cytology in urothelial carcinoma. Cancer Cell Int. 2021 Sep 6;21(1):465. doi: 10.1186/s12935-021-02169-3. PMID: 34488763; PMCID: PMC8419965.
[5] Rosolen DCB, Faria DK, Faria CS, Antonangelo L. Performance of the UroVysion® FISH assay for the diagnosis of malignant effusions using two cutoff strategies. Cancer Med. 2018 May;7(5):1967-1977. doi: 10.1002/cam4.1442. Epub 2018 Mar 25. PMID: 29577646; PMCID: PMC5943432.
[6] Wang W, Tang Y, Li J, Jiang L, Jiang Y, Su X. Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization. Cancer Cytopathol. 2015 Feb;123(2):117-22. doi: 10.1002/cncy.21510. Epub 2014 Dec 19. PMID: 25529354.
[7] Montalbo R, Izquierdo L, Ingelmo-Torres M, Galve P, Solé M, Franco A, Ribal MJ, Alcaraz A, Mengual L. Urine cytology suspicious for urothelial carcinoma: Prospective follow-up of cases using cytology and urine biomarker-based ancillary techniques. Cancer Cytopathol. 2020 Jul;128(7):460-469. doi: 10.1002/cncy.22252. Epub 2020 Feb 21. PMID: 32083810.
[8] Kinoshita Y, Hamasaki M, Matsumoto S, Yoshimura M, Sato A, Tsujimura T, Kamei T, Kawahara K, Iwasaki A, Nabeshima K. Fluorescence in situ hybridization detection of chromosome 22 monosomy in pleural effusion cytology for the diagnosis of mesothelioma. Cancer Cytopathol. 2021 Jul;129(7):526-536. doi: 10.1002/cncy.22409. Epub 2021 Jan 25. PMID: 33493384.
[9] Louw A, van Vliet C, Peverall J, Colkers S, Acott N, Creaney J, Lee YCG, Chai SM. Analysis of early pleural fluid samples in patients with mesothelioma: A case series exploration of morphology, BAP1, and CDKN2A status with implications for the concept of mesothelioma in situ in cytology. Cancer Cytopathol. 2022 May;130(5):352-362. doi: 10.1002/cncy.22548. Epub 2022 Feb 10. PMID: 35143119.
[10] Varella-Garcia M, Schulte AP, Wolf HJ, Feser WJ, Zeng C, Braudrick S, Yin X, Hirsch FR, Kennedy TC, Keith RL, Barón AE, Belinsky SA, Miller YE, Byers T, Franklin WA. The detection of chromosomal aneusomy by fluorescence in situ hybridization in sputum predicts lung cancer incidence. Cancer Prev Res (Phila). 2010 Apr;3(4):447-53. doi: 10.1158/1940-6207.CAPR-09-0165. Epub 2010 Mar 23. PMID: 20332298; PMCID: PMC2939746.
[11] Rolfo C, Mack P, Scagliotti GV, Aggarwal C, Arcila ME, Barlesi F, Bivona T, Diehn M, Dive C, Dziadziuszko R, Leighl N, Malapelle U, Mok T, Peled N, Raez LE, Sequist L, Sholl L, Swanton C, Abbosh C, Tan D, Wakelee H, Wistuba I, Bunn R, Freeman-Daily J, Wynes M, Belani C, Mitsudomi T, Gandara D. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021 Oct;16(10):1647-1662. doi: 10.1016/j.jtho.2021.06.017. Epub 2021 Jul 8. PMID: 34246791.
[12] 中华病理学杂志 2022 年 12 月第 51 卷第 12 期 Chin J Pathol, December 2022, Vol. 51, No. 12 非小细胞肺癌恶性浆膜腔积液分子病理检测中国专家共识
[13] VanderLaan PA, Roy-Chowdhuri S, Griffith CC, Weiss VL, Booth CN. Molecular testing of cytology specimens: overview of assay selection with focus on lung, salivary gland, and thyroid testing. J Am Soc Cytopathol. 2022 Nov-Dec;11(6):403-414. doi: 10.1016/j.jasc.2022.08.002. Epub 2022 Aug 19. PMID: 36184436; PMCID: PMC10225070.
[14] 中华病理学杂志 2022 年 9 月第 51 卷第 9 期 Chin J Pathol, September 2022, Vol. 51, No. 9 非小细胞肺癌细针穿刺细胞学标本 基因检测专家共识
[15] 中国肿瘤临床与康复 2023 年 10 月第 30 卷第 7 期 Chin J Clin Oncol Rehabil，October 2023，Vol. 30，No. 7 非小细胞肺癌细胞学标本上清液驱动基因 规范化检测指南(2023 年版)
[16] Nabeshima K, Hamasaki M, Kinoshita Y, Matsumoto S, Sa-Ngiamwibool P. Update of pathological diagnosis of pleural mesothelioma using genomic-based morphological techniques, for both histological and cytological investigations. Pathol Int. 2022 Aug;72(8):389-401. doi: 10.1111/pin.13235. Epub 2022 May 21. PMID: 35596704.
产品信息：
